Decreased by -2.49%
Dollar Volume
1.52 M
Earnings Report Date (estimate)
Feb 15, 23 (-0.12)
Market Cap.
551.71 M
Shares Float
36.23 M
Shares Outstanding
40.33 M
Price / Earnings
20D Range
12.02 14.49
50D Range
11.42 14.49
200D Range
9.64 23.43
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 3, 22 -0.34 -0.11
Decreased by -209.09%
Aug 4, 22 -0.03 -0.07
Increased by +57.14%
May 5, 22 0.03 -0.12
Increased by +125.00%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 76.84 M
Increased by +6.41%
-13.71 M
Decreased by -229.59%
Decreased by -17.85%
Decreased by -221.78%
Jun 30, 22 80.34 M
Increased by +5.51%
-4.26 M
Decreased by -95.55%
Decreased by -5.30%
Decreased by -85.34%
Mar 31, 22 77.21 M
Increased by +8.62%
-3.39 M
Decreased by -8.00%
Decreased by -4.39%
Increased by +0.57%
Dec 31, 21 79.39 M
Increased by +16.93%
-20.10 M
Decreased by -481.26%
Decreased by -25.32%
Decreased by -397.08%
Sep 30, 21 72.21 M
Increased by +10.86%
10.58 M
Increased by +468.71%
Increased by +14.66%
Increased by +432.58%
Jun 30, 21 76.15 M
Increased by +41.62%
-2.18 M
Increased by +40.96%
Decreased by -2.86%
Increased by +58.31%
Mar 31, 21 71.09 M
Increased by +7.01%
-3.14 M
Increased by +52.92%
Decreased by -4.41%
Increased by +56.00%
Dec 31, 20 67.90 M
Decreased by -2.58%
-3.46 M
Decreased by -407.78%
Decreased by -5.09%
Decreased by -421.25%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.